AbbVie Inc. Other Non-Current Liabilities
AbbVie Inc. (ABBV) had Other Non-Current Liabilities of $34.60 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-03
- 2026-06-30: Other Liabilities, Noncurrent $34.60B.
- 2026-03-31: Other Liabilities, Noncurrent $34.11B.
- 2025-12-31: Other Liabilities, Noncurrent $32.57B.
- 2025-09-30: Other Liabilities, Noncurrent $31.66B.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $34.60B 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $34.11B 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $32.57B 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $31.66B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $32.04B 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $31.19B 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $30.13B 10-K · filed 2026-02-20 | |
| 2024-09-30 | $33.03B 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $32.43B 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $32.78B 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $32.33B 10-K · filed 2025-02-14 | |
| 2023-09-30 | $31.64B 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $32.29B 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $32.25B 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $30.66B 10-K · filed 2024-02-20 | |
| 2022-09-30 | $30.21B 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $30.77B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $28.02B 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $28.70B 10-K · filed 2023-02-17 | |
| 2021-09-30 | $29.10B 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $28.80B 10-Q · filed 2021-08-02 | |
| 2021-03-31 | $26.87B 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $27.61B 10-K · filed 2022-02-18 | |
| 2020-09-30 | $23.38B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $23.31B 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $17.90B 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $17.60B 10-K · filed 2021-02-19 | $1.22B 10-K · filed 2020-02-21 |
| 2018-12-31 | $1.31B 10-K · filed 2020-02-21 | |
| 2017-12-31 | $1.24B 10-K · filed 2019-02-27 | |
| 2016-12-31 | $1.16B 10-K · filed 2018-02-16 | |
| 2015-12-31 | $844.00M 10-K · filed 2017-02-17 | |
| 2014-12-31 | $990.00M 10-K · filed 2016-02-19 | |
| 2013-12-31 | $1.34B 10-K · filed 2015-02-20 | |
| 2012-12-31 | $900.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |